N. Yumibe

发表

Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.

C. Montrose‐Rafizadeh, R. Thompson, W. Bensch, 2003, Journal of medicinal chemistry.

Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor α agonist

C. Montrose‐Rafizadeh, R. Thompson, W. Bensch, 2003 .

The Use of in Vitro Metabolic Stability for Rapid Selection of Compounds in Early Discovery Based on Their Expected Hepatic Extraction Ratios

I. Chu, Y. Lau, N. Yumibe, 2002, Pharmaceutical Research.

Discovery of 1‐(4‐Fluorophenyl)‐(3R)‐ [3‐(4‐fluorophenyl)‐(3S)‐hydroxypropyl] ‐(4S)‐(4‐hydroxyphenyl)‐2‐azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption.

J. Clader, T. Huynh, H. Davis, 1998 .

Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.

M. D. Leibowitz, M. Boehm, T. Grese, 2003, Bioorganic & medicinal chemistry letters.

P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors.

J. Glass, Q. Wang, Shu-Hui Chen, 2004, Bioorganic & medicinal chemistry letters.

Discovery of a novel bicycloproline P2 bearing peptidyl alpha-ketoamide LY514962 as HCV protease inhibitor.

J. Glass, B. Heinz, Q. Wang, 2004, Bioorganic & medicinal chemistry letters.

P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl alpha-ketoamide based HCV protease inhibitors.

J. Glass, Q. Wang, Robert B. Johnson, 2004, Bioorganic & medicinal chemistry letters.

Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.

A. R. Miller, S. D. Kahl, C. Hamdouchi, 2018, Journal of medicinal chemistry.

Identification of human liver cytochrome P450s involved in the microsomal metabolism of the antihistaminic drug loratadine.

M. Cayen, R. Clement, N. Yumibe, 1995, International archives of allergy and immunology.

Comparative pharmacokinetics studies of immediate- and modified-release formulations of glipizide in pigs and dogs.

G. Knipp, Robyn R. McCain, K. Ruterbories, 2012, Journal of pharmaceutical sciences.

Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.

J. Clader, T. Huynh, H. Davis, 1998, Journal of medicinal chemistry.

Metabolism and structure activity data based drug design: discovery of (−) SCH 53079 an analog of the potent cholesterol absorption inhibitor (−) SCH 48461

J. Clader, H. Davis, N. Yumibe, 1996 .

In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461.

H. Davis, K. Alton, R. Mcleod, 1997, The Journal of pharmacology and experimental therapeutics.

Metabolism and Structure Activity Data Based Drug Design: Discovery of (‐)SCH 53079 (Ia), an Analogue of the Potent Cholesterol Absorption Inhibitor (‐)SCH 48461 (Ib).

J. Clader, H. Davis, N. Yumibe, 1996 .

Design and synthesis of novel and potent amide linked PPARγ/δ dual agonists

Michael E. Laurila, L. L. Winneroski, G. Etgen, 2007 .

N-acyloxymethyl carbamate linked prodrugs of pseudomycins are novel antifungal agents.

S. Chen, D. Zeckner, X. Sun, 2001, Bioorganic & medicinal chemistry letters.

Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.

M. Snow, M. Cayen, R. Clement, 1996, Biochemical pharmacology.

Pharmacokinetics of intravenous and oral metformin and r,s-verapamil in Sinclair, Hanford, Yucatan and Göttingen minipigs

Jeffrey S. Tan, G. Bouchard, K. Ruterbories, 2017 .

Mechanistic aspects of cytochrome P-450-hydroperoxide interactions: substituent effects on degradative pathways.

J. Thompson, N. Yumibe, 1989, Drug metabolism reviews.

Fate of free radicals generated during one-electron reductions of 4-alkyl-1,4-peroxyquinols by cytochrome P-450.

J. Thompson, N. Yumibe, 1988, Chemical research in toxicology.

Fabp3 as a biomarker of skeletal muscle toxicity in the rat: comparison with conventional biomarkers.

Albert Eric Schultze, Kelly M Credille, D. Watson, 2008, Toxicological sciences : an official journal of the Society of Toxicology.

Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats

K. Cassidy, M. Mohutsky, J. Cramer, 2016, Drug Metabolism and Disposition.

Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.

M. D. Leibowitz, K. Ogilvie, M. Faul, 2006, Endocrinology.

Potential Benefits for the Treatment of Type 2 Diabetes

M. D. Leibowitz, G. Etgen, C. Broderick, 2005 .

Syn and anti bent hydrazine radical cations. Effect of .sigma.,.pi. mixing on spectral properties

J. Carpenter, F. Weinhold, T. Frigo, 1985 .

SYN AND ANTI BENT HYDRAZINE RADICAL CATIONS. EFFECT OF Σ,Π MIXING ON SPECTRAL PROPERTIES

J. Carpenter, F. Weinhold, T. Frigo, 1985 .

Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor.

F. Willard, Alma Jiménez, A. D. Showalter, 2021, Journal of Medicinal Chemistry.

The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).

C. Hamdouchi, C. Montrose‐Rafizadeh, R. Belin, 2016, Journal of medicinal chemistry.

Design and synthesis of fluorinated RXR modulators.

M. D. Leibowitz, T. Grese, R. Ardecky, 2003, Bioorganic & medicinal chemistry letters.

Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.

V. Devanarayan, J. Brozinick, C. Montrose‐Rafizadeh, 2006, Bioorganic & Medicinal Chemistry Letters.

Design and synthesis of dual peroxisome proliferator-activated receptors γ and δ agonists as novel euglycemic agents with a reduced weight gain profile

L. L. Winneroski, G. Etgen, C. Broderick, 2006 .

Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.

L. L. Winneroski, G. Etgen, C. Broderick, 2006, Journal of medicinal chemistry.

(‐)‐SCH 57939: Synthesis and Pharmacological Properties of a Potent, Metabolically Stable Cholesterol Absorption Inhibitor.

J. Clader, A. McPhail, H. Davis, 1996 .